Fibrocell to Present at 6th Annual Cell & Gene Therapy Investor Day and 2018 World Orphan Drug Congress USA
April 10 2018 - 8:00AM
Fibrocell Science, Inc. (NASDAQ:FCSC), a gene therapy company
focused on transformational autologous cell-based therapies for
skin and connective tissue diseases, today announced that John
Maslowski, President and Chief Executive Officer, will present at
the Alliance for Regenerative Medicine’s (ARM) 6th Annual Cell
& Gene Therapy Investor Day on Tuesday, April 17 at 12:10 pm
EDT in New York City and at the 2018 World Orphan Drug Congress USA
on Wednesday, April 25 at 2:00 pm EDT in Oxon Hill, Maryland.
A live webcast of Fibrocell’s presentation at
ARM’s Cell & Gene Therapy Investor Day will be available under
the investor relations section of the Company’s website at
www.fibrocell.com/investors/events and archived for 30 days.
About Fibrocell
Fibrocell is an autologous cell and gene therapy
company translating personalized biologics into medical
breakthroughs for diseases affecting the skin and connective
tissue. Fibrocell’s most advanced product candidate, FCX-007,
is the subject of a Phase 1/2 trial for the treatment of recessive
dystrophic epidermolysis bullosa (RDEB). Fibrocell is also
developing FCX-013, the Company’s product candidate for the
treatment of moderate to severe localized
scleroderma. Fibrocell’s gene therapy portfolio is being
developed in collaboration with Intrexon Corporation (NYSE:XON), a
leader in synthetic biology. For more information, visit
http://www.fibrocell.com or follow Fibrocell on Twitter at
@Fibrocell.
Trademarks
Fibrocell, the Fibrocell logo and Fibrocell
Science are trademarks of Fibrocell Science, Inc. and/or its
affiliates. All other names may be trademarks of their
respective owners.
Investor & Media Relations
Contact:Karen Casey484.713.6133kcasey@fibrocell.com
Fibrocell Science (NASDAQ:FCSC)
Historical Stock Chart
From Jun 2024 to Jul 2024
Fibrocell Science (NASDAQ:FCSC)
Historical Stock Chart
From Jul 2023 to Jul 2024